Daniel Brims
Stock Analyst at Lake Street
(0.04)
# 4,710
Out of 4,978 analysts
25
Total ratings
18.2%
Success rate
-34.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniel Brims
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Initiated Coverage: Buy | $149 | $54.11 | +175.37% | 1 | Sep 17, 2026 | |
| KURA Kura Oncology | Reiterated: Buy | $23 | $12.00 | +91.67% | 5 | Sep 10, 2026 | |
| ALGS Aligos Therapeutics | Reiterated: Buy | $45 | $5.17 | +769.99% | 3 | Aug 7, 2026 | |
| VKTX Viking Therapeutics | Initiated Coverage: Buy | $89 | $30.15 | +195.19% | 1 | May 28, 2026 | |
| RANI Rani Therapeutics Holdings | Reiterated: Buy | $9 | $0.8452 | +964.84% | 1 | May 18, 2026 | |
| LITS Lite Strategy | Reiterated: Buy | $7 | $1.05 | n/a | 7 | Sep 2, 2015 | |
| IMNN Imunon | Reiterated: Buy | $7 | $1.40 | n/a | 6 | Aug 10, 2015 | |
| TSX: BHC Bausch Health Companies Inc. | Reiterated: Buy | n/a | $8.00 | n/a | 1 | Dec 30, 2014 |
Spruce Biosciences
Sep 17, 2026
Initiated Coverage: Buy
Price Target: $149
Current: $54.11
Upside: +175.37%
Kura Oncology
Sep 10, 2026
Reiterated: Buy
Price Target: $23
Current: $12.00
Upside: +91.67%
Aligos Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $45
Current: $5.17
Upside: +769.99%
Viking Therapeutics
May 28, 2026
Initiated Coverage: Buy
Price Target: $89
Current: $30.15
Upside: +195.19%
Rani Therapeutics Holdings
May 18, 2026
Reiterated: Buy
Price Target: $9
Current: $0.8452
Upside: +964.84%
Lite Strategy
Sep 2, 2015
Reiterated: Buy
Price Target: $7
Current: $1.05
Upside: n/a
Imunon
Aug 10, 2015
Reiterated: Buy
Price Target: $7
Current: $1.40
Upside: n/a
Bausch Health Companies Inc.
Dec 30, 2014
Reiterated: Buy
Price Target: n/a
Current: $8.00
Upside: n/a